Variable domain-linked oligosaccharides of a human monoclonal IgG: structure and influence on antigen binding
- PMID: 10024532
- PMCID: PMC1220082
Variable domain-linked oligosaccharides of a human monoclonal IgG: structure and influence on antigen binding
Abstract
The variable-domain-attached oligosaccharide side chains of a human IgG produced by a human-human-mouse heterohybridoma were analysed. In addition to the conserved N-glycosylation site at Asn-297, an N-glycosylation consensus sequence (Asn-Asn-Ser) is located at position 75 in the variable region of its heavy chain. The antibody was cleaved into its antigen-binding (Fab) and crystallizing fragments. The oligosaccharides of the Fab fragment were released by digestion with various endo- and exoglycosidases and analysed by anion-exchange chromatography and fluorophore-assisted carbohydrate electrophoresis. The predominant components were disialyl- bi-antennary and tetra-sialyl tetra-antennary complex carbohydrates. Of note is the presence in this human IgG of oligosaccharides containing N-glycolylneuraminic acid and N-acetylneuraminic acid in the ratio of 94:6. Furthermore, we determined N-acetylgalactosamine in the Fab fragment of this antibody, suggesting the presence of O-linked carbohydrates. A three-dimensional structure of the glycosylated variable (Fv) fragment was suggested using computer-assisted modelling. In addition, the influence of the Fv-associated oligosaccharides of the CBGA1 antibody on antigen binding was tested in several ELISA systems. Deglycosylation resulted in a decreased antigen-binding activity.
Similar articles
-
Site-specific N-glycosylation of chicken serum IgG.Glycobiology. 2004 Mar;14(3):275-92. doi: 10.1093/glycob/cwh031. Epub 2003 Dec 23. Glycobiology. 2004. PMID: 14693911
-
Humanization of an anti-human IL-6 mouse monoclonal antibody glycosylated in its heavy chain variable region.Hum Antibodies Hybridomas. 1996;7(4):175-83. Hum Antibodies Hybridomas. 1996. PMID: 9140729
-
Structural characterization of the oligosaccharides of a human monoclonal anti-lipopolysaccharide immunoglobulin M.Glycobiology. 1998 May;8(5):497-507. doi: 10.1093/glycob/8.5.497. Glycobiology. 1998. PMID: 9597548
-
Comparison of the three-dimensional structures of a humanized and a chimeric Fab of an anti-gamma-interferon antibody.J Mol Recognit. 1999 Jan-Feb;12(1):19-32. doi: 10.1002/(SICI)1099-1352(199901/02)12:1<19::AID-JMR445>3.0.CO;2-Y. J Mol Recognit. 1999. PMID: 10398393 Review.
-
Exoglycosidases and lectins as sequencing approaches of salivary gland oligosaccharides.Histol Histopathol. 1994 Jan;9(1):173-83. Histol Histopathol. 1994. PMID: 8003813 Review.
Cited by
-
Longitudinal Pathogenic Properties and N-Glycosylation Profile of Antibodies from Patients with Pemphigus after Corticosteroid Treatment.Biomedicines. 2021 Oct 8;9(10):1411. doi: 10.3390/biomedicines9101411. Biomedicines. 2021. PMID: 34680528 Free PMC article.
-
A Comparison of Immunoglobulin Variable Region N-Linked Glycosylation in Healthy Donors, Autoimmune Disease and Lymphoma.Front Immunol. 2020 Feb 18;11:241. doi: 10.3389/fimmu.2020.00241. eCollection 2020. Front Immunol. 2020. PMID: 32133009 Free PMC article. Review.
-
Differential antibody glycosylation in autoimmunity: sweet biomarker or modulator of disease activity?Nat Rev Rheumatol. 2017 Oct;13(10):621-630. doi: 10.1038/nrrheum.2017.146. Epub 2017 Sep 14. Nat Rev Rheumatol. 2017. PMID: 28905852 Review.
-
Current advances in biopharmaceutical informatics: guidelines, impact and challenges in the computational developability assessment of antibody therapeutics.MAbs. 2022 Jan-Dec;14(1):2020082. doi: 10.1080/19420862.2021.2020082. MAbs. 2022. PMID: 35104168 Free PMC article. Review.
-
Structure, heterogeneity and developability assessment of therapeutic antibodies.MAbs. 2019 Feb/Mar;11(2):239-264. doi: 10.1080/19420862.2018.1553476. Epub 2018 Dec 17. MAbs. 2019. PMID: 30543482 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources